CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Luckwel Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Luckwel Pharmaceuticals Inc
125 Cambridge Park Drive
Suite 301
Phone: (617) 430-5222p:617 430-5222 Cambridge, MA  02140  United States

On September 20, 2021, Luckwel Pharmaceuticals Inc's Chief Executive Officer and sole director, Kingrich Lee, determined that it is appropriate to withdraw previously filed financial statements as of (i) June 30, 2020 and for the three months ended June 30, 2020, (ii) September 30, 2020 and for the three and six months ended September 30, 2020, (iii) December 31, 2020 and for the three and nine months ended December 31, 2020, and (iv) March 31, 2021 for the year ended March 31, 2021. On September 9, 2021, Marcum LLP notified the company that the withdrawal of these financial statements is necessary since Marcum had not completed its review of and had not provided the requisite authorizations to file these statements.
This company is no longer actively traded on any major stock exchange.

Business Summary
Luckwel Pharmaceuticals Inc. creates medicine to cure diseases. The Company is focused on autoimmune disease, human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS) and infectious diseases. The Company’s pipelines include LWEL-2120 for the treatment of rheumatoid arthritis (RA), LWEL-2119 for the treatment of HIV and LWEL-2103 for the treatment of COVID-19.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/20213/31/2021YesYes--Yes

Industries
SIC Code Description
6726 Unit investment trusts, face-amount certificate offices

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secr KingrichLee 46 3/1/2016 1/2/2013

Business Names
Business Name
LCOM
LKYM
Luckycom Limited
LWEL

General Information
Outstanding Shares: 147,163,500 (As of 8/31/2021)
Stock Exchange: OTC
Federal Tax Id: 461660653
Email Address: info@luckwel.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, March 23, 2024